TERN Terns Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TERN

Price (delayed)

$5.44

Market cap

$351.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.27

Enterprise value

$272.38M

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver ...

Highlights
Terns Pharmaceuticals's debt has decreased by 50% YoY and by 22% from the previous quarter
The company's EPS rose by 24% YoY but it fell by 10% QoQ
The net income is down by 49% year-on-year and by 6% since the previous quarter
Terns Pharmaceuticals's quick ratio has decreased by 34% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://ternspharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of TERN
Market
Shares outstanding
64.65M
Market cap
$351.71M
Enterprise value
$272.38M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.32
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$89.97M
EBITDA
-$89.09M
Free cash flow
-$67.44M
Per share
EPS
-$1.27
Free cash flow per share
-$0.95
Book value per share
$4.13
Revenue per share
$0
TBVPS
$3.77
Balance sheet
Total assets
$268.52M
Total liabilities
$13.15M
Debt
$603,000
Equity
$255.37M
Working capital
$255.49M
Liquidity
Debt to equity
0
Current ratio
22.39
Quick ratio
22.06
Net debt/EBITDA
0.89
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-31.9%
Return on equity
-33.5%
Return on invested capital
-51.3%
Return on capital employed
-35.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TERN stock price

How has the Terns Pharmaceuticals stock price performed over time
Intraday
2.84%
1 week
10.79%
1 month
-9.33%
1 year
-57.83%
YTD
-16.18%
QTD
-17.07%

Financial performance

How have Terns Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$102.56M
Net income
-$90.21M
Gross margin
N/A
Net margin
N/A
TERN's operating income has dropped by 65% year-on-year and by 8% since the previous quarter
The net income is down by 49% year-on-year and by 6% since the previous quarter

Growth

What is Terns Pharmaceuticals's growth rate over time

Valuation

What is Terns Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.32
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 24% YoY but it fell by 10% QoQ
The price to book (P/B) is 22% lower than the last 4 quarters average of 1.7
TERN's equity is down by 8% YoY

Efficiency

How efficient is Terns Pharmaceuticals business performance
The return on equity has declined by 8% since the previous quarter and by 3.7% year-on-year
The company's return on assets fell by 8% QoQ and by 3.2% YoY
TERN's ROIC is down by 5% YoY

Dividends

What is TERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TERN.

Financial health

How did Terns Pharmaceuticals financials performed over time
The current ratio has contracted by 34% YoY
Terns Pharmaceuticals's quick ratio has decreased by 34% YoY
Terns Pharmaceuticals's debt is 100% less than its equity
Terns Pharmaceuticals's debt has decreased by 50% YoY and by 22% from the previous quarter
TERN's equity is down by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.